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Summary Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared
with conventional bolus therapy. As a first line of chemotherapy in proven metastatic breast carcinoma, 258 women were randomly assigned
to receive FAC consisting of 5-fluorouracil (F) 600 mg m-2 intravenously (i.v.) over 1 h on days 1, 2 and 3, doxorubicin (A) 50 mg m-2 i.v. bolus
on day 1 and cyclophosphamide (C), 400 mg m-2 i.v. bolus on days 1, 2 and 3 or 'FULON' consisting of 5-fluorouracil 250 mg m-2 day-1
continuously infused from day 1 to day 22, doxorubicin 15 mg m-2 i.v. bolus on days 1, 8, 15 and 22 and cyclophosphamide 300 mg m-2 i.v.
bolus on days 1, 8, 15 and 22. Chemotherapy courses were administered 4-weekly for the bolus regimen and 6-weekly for FULON.
Pretreatment characteristics were identical between the two groups. Response rates were 54% in the FAC arm and 53% in the FULON arm.
Time to progression was 14 months in the FAC arm and 12 months in the FULON arm. Differences were not statistically significant. Median
overall survival duration for all patients was 22 months. Haematological toxicity was more severe in the bolus-treated group (P = 0.05), as
were nausea and vomiting (P < 0.01). We conclude that the two regimens appeared equally effective but have different toxicities.
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The aim of conventional chemotherapy in clinically disseminated
breast cancer is to palliate symptoms and to improve the quality of
life. Using conventional chemotherapy regimens in metastatic
breast cancer, response rates of 50% to 60% are commonly
achieved (Jones et al, 1994). Combination chemotherapy has also
been shown to prolong the survival of these patients from first
recurrence, although there has not been a significant improvement
in long-term survival in the past ten years. Until more effective
chemotherapeutic regimens that result in durable remissions are
developed, a significant decrease in mortality rate will not be
observed (Ross et al, 1985).
A correlation between increased dose intensity and better
outcome has been described in metastatic disease (Hryniuk et al,
1986). Dose intensity could also be increased by the use of low-
dose continuous infusion chemotherapy (Lokich and Anderson,
1995). The response rate to single-agent 5-fluorouracil adminis-
tered by short infusion was 26% in an overview of 1263 breast
cancer patients (Carter, 1976). 5-FU is an S-phase-specific agent
with a short serum half-life of 10-20 min owing to rapid catabo-
lism to its metabolites (Fraile et al, 1980), supporting a rationale
for continuous infusion over bolus administration. Continuous
infusion 5-FU has been used in several phase II studies against
solid tumours. Significant activity has been demonstrated against
colorectal carcinoma and breast cancer, with response rates
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ranging from 32% (Hansen et al, 1987) to 53% (Huan et al, 1989).
Doses of 300 to 350 mg m-2 day-1 for infusions lasting more than
30 days were achieved in early studies (Lokich et al, 1981). The
breast cancer studies included some patients who responded to
infusional 5-FU and were previously resistant to bolus therapy
(Hansen, 1991). A recent, detailed review of infusional 5-FU in
advanced breast cancer has concluded that this administration is
associated with superior clinical response rates over conventional
bolus therapy (Anderson, 1993).
Using a continuous infusion of 5-FU over a twice-monthly, 5-
day course (days 1-5 and 15-19) associated with 4-weekly injec-
tions ofdoxorubicin, cyclophosphamide and vindesine on days 2,
5, 16 and 19, we have reported previously an objective response
rate of74% with acomplete response rate of28% in a small series
of48 patients with metastatic breastcarcinoma (Jouve et al, 1989).
Median response and survival duration was 18 and 27 months
respectively. In a second trial, we treated 34 notpreviously treated
metastatic breast cancer patients and 49 patients with a previous
regimen, with a combination of a continuous ambulatory venous
infusion of 5-FU 350 mg m-2 day-' and oral cyclophosphamide
100 mg m2day- over 15 days, togetherwith a weekly administra-
tion of vincristine (0.8 mg m-2) and doxorubicin (15 mg m-2) on
days 1, 8 and 15. The overall response rates were 55% in
chemotherapy-naive and 42% in pretreated patients (Raymond et
al, 1996). Tolerance was better than in our previous combination.
A similar regimen has been reported to give an 83% response rate
in the first line ofchemotherapy in advanced breastcancerpatients
(Gordon et al, 1990).
The aim of the present study was to compare the efficacy of
a continuous infusion of 5-fluorouracil together with weekly
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doxorubicin and cyclophosphamide administration with a 'clas-
sical' monthly regimen of the same drugs as the first line of
chemotherapy in metastatic breast carcinoma.
PATIENTS AND METHODS
Patients
Patients had to be above 18 years of age and to have histologically
confirmed carcinoma ofthe breast, metastatic disease with lesions
that could be evaluated. Patients who had received any chemo-
therapy for metastatic disease were excluded. Patients were ineli-
gible ifthey had a granulocyte count ofless than 1.5 x 1091-1 or a
platelet count of less than 100 x 109 1-1, unless myelosuppression
was caused by bone marrow involvement. Patients were also
excluded ifthey had a bilirubin level 2 1.5 times normal, a history
of congestive heart failure or had brain metastases as the only
evidence of tumour spread. Patients were allowed to undergo
concurrent irradiation provided that they had assessable or
measurable disease outside the field ofirradiation.
Treatment protocol
Patients were randomly assigned to receive either FAC bolus
chemotherapy or FULON infusional chemotherapy. FAC
consisted of5-fluorouracil (F), 600 mg i-2 i.v. over 1 h on days 1,
2 and 3, doxorubicin (A), 50 mg m-2 i.v. bolus on day 1 and
cyclophosphamide (C), 400 mg m-2 i.v. bolus on days 1, 2 and 3.
FULON consisted of 5-fluorouracil, 250 mgM-2 per day
continuously infused from day 1 to day 22, cyclophosphamide,
300 mg m-2 i.v. bolus on days 1, 8, 15 and 22 and doxorubicin,
15mgm-2 i.v. bolus on days 1, 8, 15 and 22. Chemotherapy
courses were re-administered on a 4-weekly basis for the FAC
regimen and every 6 weeks for FULON, provided the granulocyte
count was above 1.5 x 109 1-1, platelets were above 100 x 109 1-'
and the non-haematological toxicities hadrecovered completely. A
central venous catheter was inserted in all patients before the initi-
ation ofthe FULON regimen. Tumour response was assessed after
4 months (i.e. after four FAC courses or three FULON courses).
Treatment was continued in responders and stopped in cases of
tumour progression. For patients with minor response or stable
disease, treatment could be continued if well tolerated or crossed
over to the other arm oftreatment. A second evaluation procedure
was at 8 months. Chemotherapy was stopped at 12 months or at
tumourprogression. Prophylactic anti-fungal regimen consisted of
cordosyl mouthwash with 50 mg of fluconazole daily for 10 days
forpatients with aprevious episode ofmucositis.
Evaluation procedures
Pretreatment evaluation included a complete history and physical
examination, measurement ofall palpable lesions, complete blood
counts, liver function tests, renal function tests, measurements of
serum electrolytes and calcium, chest radiograph and radionuclide
bone scan. Patients with abnormal bone scans had conventional
radiological examinations of areas ofincreased uptake. A comput-
erized tomographic scan ofthe head was required forpatients with
neurological symptoms. The complete blood count was repeated
before each course oftherapy; the biochemical tests were repeated
if abnormal values requiring dose modification were found before
any treatment orforthe evaluation ofnew orworsening symptoms.
A physical examination was performed before each cycle. Chest
radiographs were also repeated before each cycle. All metastatic
sites were re-evaluated with appropriate scanning and radiographic
films at 4, 8, 12 and 18 months.
Assessment of response
A complete response (CR) was defined as the disappearance ofall
known metastases. A partial response (PR) was defined as a
decrease of 50% or more in the product of the longest perpendic-
ulardiameters ofmeasurable lesions. Patients with aless than 50%
decrease in the size of measurable metastases (which excluded
bone lesions) were considered to have stable disease (SD). Those
who had more than a 25% increase in the size of any measurable
lesion orin whom a new lesion developed were considered to have
progressive disease (PD). Time to progression was defined as the
time from randomization until disease progression or the last day
offollow-up. Survival was calculated as the time from randomiza-
tion until death or the last day of follow-up. Early death before
response assessment was recorded as tumourprogression.
Toxicity
Toxicity was assessed according to the WHO criteria (Miller et al,
1981). The most severe toxicity grade was recorded perpatient.
Table 1 Pretreatment characteristics of the 258 patients with metastatic
breast cancer
Characteristics All patients FAC FULON Chi
(n = 258) group group square
(n = 131) (n = 127) test
Median age (years) (range) 55 (24-75) 55 (24-75) 55 (28-70)
Menopause 134 (52%) 66 (50%) 68 (53%) NS
Karnofsky index > 60 238 (92%) 122 (93%) 116 (91%) NS
Median DFla (months) 36 35 37 NS
One metastatic site 104 (40%) 57 (44%) 47 (37%) NS
Two sites 74 (29%) 39 (30%) 35 (28%)
Three sites or more 80 (31%) 35 (27%) 45 (35%)
Histology (SBR)
40 (15%) 19 (14%) 21 (17%) NS
11 128 (50%) 72 (55%) 56 (44%)
lii 49 (19%) 22 (17%) 27 (21%)
Unknown 41 (16%) 18 (14%) 23 (18%)
Oestrogen receptor (ER)
ER+ 118 (45%) 58 (44%) 60 (47%) NS
ER- 69 (27%) 39 (30%) 30 (24%)
Unknown 71 (28%) 34 (26%) 37 (29%)
Progesterone receptor (PR)
PR+ 97 (38%) 44 (34%) 53 (41%) NS
PR- 98 (38%) 54 (41%) 44 (35%)
Unknown 63 (24%) 33(25%) 30 (24%)
LDH
< 330 Ul l-1 183 (71%) 86 (66%) 97 (76%) NS
> 330 Ul l-' 57 (22%) 36 (27%) 21 (17%)
Missing 18 (7%) 9 (7%) 9 (7%)
Previous treatment NS
Adjuvant chemotherapy 86 (33%) 41 (31%) 45 (35%)
Hormone therapy 48 (19%) 20 (15%) 28 (22%)
aDisease-free interval from diagnosis to metastasis.
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Table 2 Sites of disease
Sites All patients FAC FULON Chi-square
(n = 258) group group test
(n = 131) (n = 127) NS
Bone 133 (52%) 66 (51%) 67 (53%)
Lung 64 (25%) 35 (27%) 29 (23%)
Pleura 38 (15%) 18 (14%) 20 (16%)
Liver 82 (32%) 41 (31%) 41 (32%)
Skin 45 (17%) 21 (16%) 24 (19%)
Nodes 71 (28%) 30 (23%) 41 (32%)
Table 3 Response rates
All patients FAC FULON Chi-square
(n = 258) group group test
(n = 131) (n = 127)
Response at 4 months 0.20 (NS)
CR 25 (10%) 13(10%) 12 (9%)
PR 114 (44%) 58 (44%) 56 (44%)
SD 70 (27%) 41 (31%) 29 (23%)
PD 49 (19%) 19 (15%) 30 (24%)
Response at 8 months 0.81 (NS)
CR 36 (14%) 19(15%) 17(13%)
PR 103 (40%) 55 (42%) 48 (38%)
SD 31 (12%) 16 (12%) 15 (12%)
PD 88 (34%) 41 (31%) 48 (37%)
Table 4 Factors influencing survival using multivariate Cox regression
analysis
Parameters RR 95% Cl P-value
LDH levels
<330Ul 1- 1 1.9-4.5 <0.001
> 330 UI 1- 3.0
Number of involved sites
<3 1 1.5-3.5 <0.001
23 2.3
Progesterone receptor
PR+ 1 1.2-2.6 0.002
PR- 1.8
Liver metastasis
No 1 1.1-2.5 0.004
Yes 1.7
Karnofsky index
> 60 1 1.5-5.5 0.008
<60 3.0
Previous chemotherapy
No 1 1.1-2.5 0.02
Yes 1.7
RR, relative risk; 95% Cl, 95% confidence interval.
toxicity) (Goldhirsch et al, 1989). This questionnaire was
composed of 13 items. Toxicity was considered to be present when
the patient reported at least one ofthose 13 symptoms.
Statistical analysis
Simple random sampling was used to allocate patients to treat-
ment, and intention-to-treat analyses were used. Differences
between treatment groups were analysed by chi-square tests for
categorical variables and Student's t-test for continuous variables.
The survival and response duration curves were determined using
a Kaplan-Meier product-limit method (Kaplan and Meier, 1958).
Statistical significance between treatment groups was assessed
using the log rank test. Multivariate analysis was carried out to
assess the relative influence ofprognostic factors on response and
overall survival, using the Cox proportional hazard model in a
forward stepwise procedure (Cox, 1972). The Breslow test was
used to compare different samples subject to unequal patterns of
censorship (Breslow, 1970).
Figure 1 Time to progression in the two groups. A, FAC median at
14 months; B, FULON median at 12 months
Quality of life assessment
The quality of life assessment was based both on the Rosser and
Kind (1978) index as well as on the HMQ questionnaire (Fagnani
et al, 1992). Patients received the questionnaire by mail. When
patients were notjudged able to answerthe questions on theirown,
index (disability and distress) was established by the investigator.
A complementary study was carried out by submitting a subgroup
of patients to a toxicity-oriented self-questionnaire, according to
Gelber and Goldhirsch who proposed the Q-TWiST (quality-
adjusted survival analysis relative to time without symptoms and
RESULTS
Between January 1990 and June 1993, 258 metastatic breast
cancer patients who met all the eligibility criteria were included in
this study. The pretreatment characteristics ofthese patients in the
two groups were not statistically different (Table 1). The distribu-
tion ofthe metastatic sites is given in Table 2.
The objective response rate for all patients was 54%. Objective
response rates according to FAC or FULON regimens were not
significantly different: 54% vs 53% at 4 months and 56% vs 52%
at 8 months (Table 3). Twenty-three patients in the FAC group and
32 in the FULON group finally crossed over after 4 months of
treatment. At 8 months, response rates for patients who had not
crossed over were 58% and 57% in the FAC and FULON arms
respectively. Median overall survival duration for all patients was
22 months, and median time to progression was 14 months. There
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Table 5 Toxicity
Toxicity (WHO) FAC FULON P-value
group group (chi-square
(n= 131) (n= 127) test)
Haematotoxicity 26 (20%) 14 (11%) 0.05
(2grade 3)
Infection 18 (14%) 10 (8%) NS
(2 grade 3)
Vomiting 14 (11%) 3 (3%) < 0.01
(2 grade 3)
Stomatitis 11(8%) 11(8%) NS
(2grade 3)
Diarrhoea 5 (4%) 9 (7%) NS
(2 grade 3)
Palmar-plantarsyndrome 1 (1%) 5 (5%) NS
(2grade 3)
Alopecia 126 (96%) 83 (65%) < 0.001
(. grade 2)
-- :
: . . ... . .~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~j
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Figure 2 (A) Survival according to the LDH levels (n = 240, LDH missing in
18 patients). (-) LDH < 330; (-- -) LDH > 330. (B) 'Survival according to
liver metastasis. (-) No liver metastasis; (--- -) liver metastasis
were no statistically significant differences between the two
groups, as shown in Figure 1. Mean duration of treatment was
8.8 months [standard deviation (s.d.) 4 months].
Prognostic factors for survival, as established in a multivariate
Cox regression model, are shown in Table 4. Pejorative prognostic
factors for survival in these patients with metastatic breast cancer
were elevation of lactate dehydrogenase (LDH) levels (Figure
2A), increasing number of metastatic sites, absence of proges-
terone receptor expression, presence of liver metastasis (Figure
2B), a low Kamofsky index (< 60) and a history of previous adju-
vant chemotherapy. For all these parameters, there was no differ-
ence in either treatment arm.
Tolerance was better in the continuous infusion arm, as shown
in Table 5. Haematological toxicity was more severe in the FAC
group (P = 0.05), as was nausea and vomiting (P < 0.01). There
were no statistically significant differences in the occurrence of
mucositis and diarrhoea. Ten patients had to be hospitalized at
least once for toxicity in the FAC group compared with five in the
FULON group (NS). There were three cases of congestive heart
failure secondary to anthracyclines (two in the FAC group and one
in the FULON group). There were four toxic deaths, three in the
FAC group (one congestive heart failure, one hepatic failure and
one febrile neutropenia) and one in the FULON group as a result
of febrile neutropenia.
A total of 261 quality of life measures were collected (some
patients were interviewed twice or even three times). The mean
quality of life value was 0.82. The comparison of the mean quality
of life values between the two groups (0.83 and 0.80 for FAC and
FULON respectively) showed no statistically significant differ-
ence. No difference was found when considering the last treatment
given before interview. The complementary questionnaires, which
explored the toxicity alone, were filled in 72 times by 43 patients.
Toxicity was reported during FAC and FULON treatment by 91%
and 71% of patients respectively (P < 0.05). This difference lost
statistical significance when alopecia was excluded.
DISCUSSION
Combination chemotherapy with infusional 5-FU is able to provide
a high response rate in breast cancer. A response rate of 84% in a
series of 43 patients with metastatic or locally advanced breast
cancer has been published. These patients had been treated with a
combination of 5-FU 200 mg mi-2 day-' via an ambulatory pump
for 6 months with epirubicin 50 mg in-2 i.v. and cisplatin 60 mg m-2
i.v. (ECF) every 3 weeks for eight courses (Jones et al, 1994).
Similar results have been achieved by the same team with a combi-
nation in which carboplatin had been substituted for cisplatin
(Bonnefoi et al, 1996). The original ECF regimen was also able to
provide an overall response rate of 98% with 66% complete remis-
sion in a series of 50 patients with large primary potentially oper-
able breast cancers (Smith et al, 1995). More recently, Gabra et al
(1996) reported a response rate of 76% in locoregionally recurrent
and metastatic breast cancer with a regimen ofweekly doxorubicin
and continuous infusional 5-fluorouracil.
A favourable overall response rate of 54% was obtained in our
trial with the FULON regimen. In this trial, FULON appeared to
British Journal of Cancer (1998) 77(9), 1474-1479
A
0CancerResearch Campaign 19981478 J-YPierga etal
be equivalent to the FAC regimen in terms of response rate and
overall survival. Median overall survival duration for all patients
was 22 months, and median response duration was 14 months,
similar to published data on chemotherapy in metastatic breast
cancer (Ross et al, 1985).
FULON was better tolerated than FAC in terms ofhaematolog-
ical toxicity and nausea and vomiting. Overall drug-related toxicity
for all patients during either of these treatments was acceptable.
Mucositis was considerably reduced in both groups by systematic
prevention with anti-fungicides. Toxicity with infusional therapy
appears not to be greater than with intermittent bolus treatment,
although individual toxicities may differ. Myelosuppression is
reduced with infusional treatments, whereas stomatis and diarrhoea
may be greater. The lack of an increase in toxicity with infusional
chemotherapy is all the more impressive when one considers that
the total dose per month is increased overthe dose permonthgiven
with standard conventional chemotherapy (Smith et al, 1995).
There was no significant difference in terms of quality of life
between the FAC and FULON treatments.
Factors associated with poor response rates and decreased
overall survival in our study were increased LDH levels, the
number of involved sites, progesterone receptor negativity, liver
involvement, poor performance status and previous adjuvant
chemotherapy. Extent of disease and poor performance status are
classically associated with poor survival in metastatic breast
cancer (Hortobagyi et al, 1983). An association between previous
adjuvant treatment and poor response to treatment on relapse was
first suggested in 1981 (Chlebowski et al, 1981). More recent
studies have confirmed this observation (Bonneterre and Mercier,
1993; Houston et al, 1993; Rubens, 1993). LDH level is not a
usual prognostic factor described in the literature for metastatic
breast cancer, but this parameter has a very strong correlation
with poor survival in our series. For all ofthese parameters, there
was no significant difference when adjusted for chemotherapy
modality group.
Although anthracyclines are the most active single agents in
patients with breast cancer, toxicity can be severe in patients with
impaired liver function and reduced hepatic clearance (Benjamin
et al, 1974). In patients with apoorperformance status orlow bone
marrow reserve, massive liver involvement or lymphangitic
pulmonary metastases, weekly administration of 15-20 mg m-2
doxorubicin is associated with fewer complications without a
reduction in its effectiveness compared with the conventional dose
of 50-75 mg m-2 every 3 weeks, as shown by Scheithauer et al
(1985). Patients with breast cancer and liver metastases who have
abnormal biochemistry have been treated efficiently with weekly
epirubicin 25 mg m-2, with adjustments of dose intensity for
myelosuppression in 36 cases (Twelves et al, 1989). Elimination of
anthracyclines may be delayed in patients with liver dysfunction,
increasing the dose intensity of doxorubicin in a weekly regimen
such as FULON without an increase in toxicity.
Nevertheless, a low weekly dose of doxorubicin might be less
effective than a higher monthly dose, as reported in the random-
ized trial ofBlomqvist et al (1992). In this study, 174 patients with
metastatic breast cancer previously untreated with anthracycline
cytotoxic agents were randomized into one group receiving FEC
(5-fluorouracil, 500 mg m-2, epirubicin, 60 mg m-2 and cyclophos-
phamide, 500 mg m-2) once every 4 weeks and another group
receiving the treatment once a week in the same monthly dosage.
Monthly FEC gave significantly higherresponse rates than weekly
treatments (52% vs 34%, P = 0.01). Time to progression and
overall survival were significantly longer with monthly FEC.
Haematological toxicity was significantly more severe in the
monthly group, as was nausea and vomiting. Both efficacy and
toxicity increased when the treatment was given once a month
compared with the weekly schedule.
One explanation of the lower efficiency of the weekly regimen
could be the early induction of MDRJ gene expression or the
selection of primary resistant cells by repeated low doses of
anthracycline as shown in vitro. Early expression of MDRJ has
been demonstrated recently in a neoadjuvant regimen for breast
cancer, appearing during the first month oftreatment. This expres-
sion was correlated with response to chemotherapy (Chevillard et
al, 1996). Anotherpoint is thatthe theoretical total dose ofdoxoru-
bicin was 10% lower in the FULON regimen compared with the
FAC regimen. Dose intensity of delivered doxorubicin has not
been assessed in this study.
We conclude that the two regimens, FAC and FULON, seem to
be equally effective as a first line of chemotherapy in metastatic
breast cancer. Toxicity ofthe FULON regimen seems to be lower.
Continuous infusion vs bolus infusion of 5-FU cannot be
compared, as the administration of doxorubicin and cyclophos-
phamide varies between the two regimens. In the FULON arm, the
efficiency of continuous infusion of 5-FU could have been
lowered by a weekly instead ofa monthly delivery ofdoxorubicin
and cyclophosphamide. The continuous infusion of 5-FU associ-
ated with monthly classical delivery of doxorubicin and
cyclophosphamide should be investigated further.
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